154 related articles for article (PubMed ID: 27235014)
21. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability.
Bellido T; Plotkin LI
Bone; 2011 Jul; 49(1):50-5. PubMed ID: 20727997
[TBL] [Abstract][Full Text] [Related]
22. Inhibited osteoclastic bone resorption through alendronate treatment in rats reduces severe osteoarthritis progression.
Siebelt M; Waarsing JH; Groen HC; Müller C; Koelewijn SJ; de Blois E; Verhaar JA; de Jong M; Weinans H
Bone; 2014 Sep; 66():163-70. PubMed ID: 24933343
[TBL] [Abstract][Full Text] [Related]
23. Osteoblast proliferation and maturation by bisphosphonates.
Im GI; Qureshi SA; Kenney J; Rubash HE; Shanbhag AS
Biomaterials; 2004 Aug; 25(18):4105-15. PubMed ID: 15046901
[TBL] [Abstract][Full Text] [Related]
24. Vascular action of bisphosphonates: In vitro effect of alendronate on the regulation of cellular events involved in vessel pathogenesis.
Cutini PH; Rauschemberger MB; Sandoval MJ; Massheimer VL
J Mol Cell Cardiol; 2016 Nov; 100():83-92. PubMed ID: 27705747
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of crude bone morphogenetic protein-induced new bone formation and normalization of endochondral ossification by bisphosphonate treatment in osteoprotegerin-deficient mice.
Tabuchi M; Miyazawa K; Kimura M; Maeda H; Kawai T; Kameyama Y; Goto S
Calcif Tissue Int; 2005 Oct; 77(4):239-49. PubMed ID: 16193235
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone.
Weinstein RS; Jilka RL; Parfitt AM; Manolagas SC
J Clin Invest; 1998 Jul; 102(2):274-82. PubMed ID: 9664068
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption.
Vitté C; Fleisch H; Guenther HL
Endocrinology; 1996 Jun; 137(6):2324-33. PubMed ID: 8641182
[TBL] [Abstract][Full Text] [Related]
28. IL-6 alters osteocyte signaling toward osteoblasts but not osteoclasts.
Bakker AD; Kulkarni RN; Klein-Nulend J; Lems WF
J Dent Res; 2014 Apr; 93(4):394-9. PubMed ID: 24492932
[TBL] [Abstract][Full Text] [Related]
29. Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate.
Lezcano V; Bellido T; Plotkin LI; Boland R; Morelli S
Exp Cell Res; 2014 May; 324(1):30-9. PubMed ID: 24698731
[TBL] [Abstract][Full Text] [Related]
30. Histological examination on osteoblastic activities in the alveolar bone of transgenic mice with induced ablation of osteocytes.
Li M; Hasegawa T; Hogo H; Tatsumi S; Liu Z; Guo Y; Sasaki M; Tabata C; Yamamoto T; Ikeda K; Amizuka N
Histol Histopathol; 2013 Mar; 28(3):327-35. PubMed ID: 23348386
[TBL] [Abstract][Full Text] [Related]
31. Effects of combined treatment with eldecalcitol and alendronate on bone mass, mechanical properties, and bone histomorphometry in ovariectomized rats: a comparison with alfacalcidol and alendronate.
Sugimoto M; Futaki N; Harada M; Kaku S
Bone; 2013 Jan; 52(1):181-8. PubMed ID: 23041510
[TBL] [Abstract][Full Text] [Related]
32. Osteocyte apoptosis is induced by weightlessness in mice and precedes osteoclast recruitment and bone loss.
Aguirre JI; Plotkin LI; Stewart SA; Weinstein RS; Parfitt AM; Manolagas SC; Bellido T
J Bone Miner Res; 2006 Apr; 21(4):605-15. PubMed ID: 16598381
[TBL] [Abstract][Full Text] [Related]
33. The effect of alendronate on resorption of the alveolar bone following tooth extraction.
Altundal H; Güvener O
Int J Oral Maxillofac Surg; 2004 Apr; 33(3):286-93. PubMed ID: 15287313
[TBL] [Abstract][Full Text] [Related]
34. Effect of continuous and intermittent sodium alendronate oral dosing on post-extraction alveoli healing in rats.
Isaias PHC; Silva PGB; do Nascimento IV; Verde MEQL; Moreira MDS; Alves APNN; Sousa FB; Pereira KMA; Mota MRL
Arch Oral Biol; 2021 Dec; 132():105291. PubMed ID: 34700193
[TBL] [Abstract][Full Text] [Related]
35. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
[TBL] [Abstract][Full Text] [Related]
36. The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice.
Johnston S; Andrews S; Shen V; Cosman F; Lindsay R; Dempster DW; Iida-Klein A
Endocrinology; 2007 Sep; 148(9):4466-74. PubMed ID: 17569757
[TBL] [Abstract][Full Text] [Related]
37. Study on in vitro release and cell response to alendronate sodium-loaded ultrahigh molecular weight polyethylene loaded with alendronate sodium wear particles to treat the particles-induced osteolysis.
Qu S; Bai Y; Liu X; Fu R; Duan K; Weng J
J Biomed Mater Res A; 2013 Feb; 101(2):394-403. PubMed ID: 22847941
[TBL] [Abstract][Full Text] [Related]
38. Structurally different bisphosphonates exert opposing effects on alkaline phosphatase and mineralization in marrow osteoprogenitors.
Klein BY; Ben-Bassat H; Breuer E; Solomon V; Golomb G
J Cell Biochem; 1998 Feb; 68(2):186-94. PubMed ID: 9443074
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates: effects on osteoblast.
Maruotti N; Corrado A; Neve A; Cantatore FP
Eur J Clin Pharmacol; 2012 Jul; 68(7):1013-8. PubMed ID: 22318756
[TBL] [Abstract][Full Text] [Related]
40. Alendronate alters osteoblast activities.
Krüger TB; Herlofson BB; Landin MA; Reseland JE
Acta Odontol Scand; 2016 Oct; 74(7):550-557. PubMed ID: 27546224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
